Search Results - "DONSKOV, F"

Tumour-associated CD66b+ neutrophil count is an independent prognostic factor for recurrence in localised cervical cancer by Carus, A, Ladekarl, M, Hager, H, Nedergaard, B S, Donskov, F

“…Background: The prognostic impact of tumour-promoting immune cells in cervical cancer is unclear. Methods: Federation of Gynaecology and Obstetrics (FIGO)…”
Get full text

Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy by Heng, D.Y., MacKenzie, M.J., Vaishampayan, U.N., Bjarnason, G.A., Knox, J.J., Tan, M.H., Wood, L., Wang, Y., Kollmannsberger, C., North, S., Donskov, F., Rini, B.I., Choueiri, T.K.

“…A subset of patients treated with initial anti-vascular endothelial growth factor (VEGF) therapy exhibit progressive disease (PD) as the best response per…”
Get full text

Hyponatremia associates with poor outcome in metastatic renal cell carcinoma patients treated with everolimus: prognostic impact by Penttilä, P, Bono, P, Peltola, K, Donskov, F

“…The prognostication of metastatic renal cell carcinoma (mRCC) is based on Memorial Sloan Kettering Cancer Center (MSKCC) and International Metastatic Renal…”
Get more information

Everolimus-induced pneumonitis associates with favourable outcome in patients with metastatic renal cell carcinoma by Penttilä, P, Donskov, F, Rautiola, J, Peltola, K, Laukka, M, Bono, P

“…Abstract Background Mammalian target of rapamycin inhibitors may induce pneumonitis. We analysed the association of pneumonitis with outcomes in everolimus…”
Get full text

Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials by Heng, D.Y.C., Choueiri, T.K., Rini, B.I., Lee, J., Yuasa, T., Pal, S.K., Srinivas, S., Bjarnason, G.A., Knox, J.J., MacKenzie, M., Vaishampayan, U.N., Tan, M.H., Rha, S.Y., Donskov, F., Agarwal, N., Kollmannsberger, C., North, S., Wood, L.A.

“…Targeted therapies in metastatic renal cell carcinoma (mRCC) have been approved based on registration clinical trials that have strict eligibility criteria…”
Get full text

Hyponatremia as a prognostic and predictive factor in metastatic renal cell carcinoma by Jeppesen, A N, Jensen, H K, Donskov, F, Marcussen, N, von der Maase, H

“…Background: Low serum sodium has recently been associated with poor survival in localised renal cell carcinoma (RCC). We now show the prognostic effect of…”
Get full text

Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial by Staehler, M., Motzer, R.J., George, D.J., Pandha, H.S., Donskov, F., Escudier, B., Pantuck, A.J., Patel, A., DeAnnuntis, L., Bhattacharyya, H., Ramaswamy, K., Zanotti, G., Lin, X., Lechuga, M., Serfass, L., Paty, J., Ravaud, A.

“…Adjuvant sunitinib has significantly improved disease-free survival versus placebo in patients with renal cell carcinoma at high risk of recurrence…”
Get full text

First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC by Ko, J J, Choueiri, T K, Rini, B I, Lee, J-L, Kroeger, N, Srinivas, S, Harshman, L C, Knox, J J, Bjarnason, G A, MacKenzie, M J, Wood, L, Vaishampayan, U N, Agarwal, N, Pal, S K, Tan, M-H, Rha, S Y, Yuasa, T, Donskov, F, Bamias, A, Heng, D Y C

“…Background: Limited data exist on outcomes for metastatic renal cell carcinoma (mRCC) patients treated with multiple lines of therapy. Benchmarks for survival…”
Get full text

Impact of comorbidity on renal cell carcinoma prognosis: a nationwide cohort study by Horsbøl, T A, Dalton, S O, Christensen, J, Petersen, A C, Azawi, N, Donskov, F, Holm, M L, Nørgaard, M, Lund, L

“…Presence of comorbid diseases at time of cancer diagnosis may affect prognosis. We evaluated the impact of comorbidity on survival of patients diagnosed with…”
Get more information

Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium by Stukalin, I, Wells, J C, Graham, J, Yuasa, T, Beuselinck, B, Kollmansberger, C, Ernst, D S, Agarwal, N, Le, T, Donskov, F, Hansen, A R, Bjarnason, G A, Srinivas, S, Wood, L A, Alva, A S, Kanesvaran, R, Fu, S Y F, Davis, I D, Choueiri, T K, Heng, D Y C

“…In the present study, we explored the real-world efficacy of the immuno-oncology checkpoint inhibitor nivolumab and the tyrosine kinase inhibitor cabozantinib…”
Get full text

711P Nivolumab + ipilimumab (N+I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy by Albiges, L., Tannir, N., Burotto, M., McDermott, D.F., Plimack, E.R., Barthélémy, P., Porta, C.G., Powles, T.B., Donskov, F., George, S., Kollmannsberger, C., Gurney, H., Grimm, M-O., Tomita, Y., Castellano Gauna, D., Rini, B.I., Choueiri, T.K., Saggi, S.S., McHenry, M.B., Motzer, R.J.

Get full text

First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Updated follow-up for KEYNOTE-427 cohort B by Suárez, C., Lee, J.-L., Ziobro, M., Gafanov, R.A., Matveev, V.B., Donskov, F., Pouliot, F., Alekseev, B.Y., Wiechno, P.J., Tomczak, P., Climent, M.A., Shin, S.J., Kloss Silverman, R., Perini, R.F., Schloss, C., McDermott, D.F., Atkins, M.B.

Get full text

Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis by McDermott, D.F., Rini, B.I., Motzer, R.J., Tannir, N.M., Escudier, B., Kollmannsberger, C.K., Hammers, H.J., Porta, C., George, S., Donskov, F., Gurney, H.P., Grimm, M.-O., Harrison, M., Hutson, T.E., Doan, J., Yang, S., Rao, S., Mekan, S., Ambavane, A., Powles, T.

Get full text

KEYNOTE-427 cohort A: Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC) by Donskov, F., McDermott, D.F., Lee, J.L., Szczylik, C., Malik, J., Alekseev, B.Y., Larkin, J.M.G., Matveev, V.B., Airatovich Gafanov, R., Tomczak, P., Tykodi, S.S., Geertsen, P.F., Wiechno, P., Shin, S.J., Pouliot, F., Alonso Gordoa, T., Kloss Silverman, R., Perini, R.F., Schloss, C., Atkins, M.B.

Get full text

Clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) and mammalian target of rapamycin inhibitors (mTORI) after immuno-oncology (IO) checkpoint inhibitors by Graham, J., Wells, J.C., McKay, R., Vaishampayan, U.N., Hansen, A., Donskov, F., Bjarnason, G.A., Beuselinck, B., De Velasco, G., Duh, M.S., Huynh, L., Chang, R., Zanotti, G., Ramaswamy, K., Choueiri, T.K., Heng, D.Y.C.

Get full text

Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma receiving first-line combination immunotherapies: results from the International Metastatic Renal Cell Carcinoma Database Consortium by Takemura, K., Yuasa, T., Lemelin, A., Ferrier, E., Wells, J.C., Saad, E., Saliby, R.M., Basappa, N.S., Wood, L.A., Jude, E., Pal, S.K., Donskov, F., Beuselinck, B., Szabados, B., Powles, T., McKay, R.R., Gebrael, G., Agarwal, N., Choueiri, T.K., Heng, D.Y.C.

“…Lymphocytes are closely linked to mechanisms of action of immuno-oncology (IO) agents. We aimed to assess the prognostic significance of absolute lymphocyte…”
Get full text

Safety and tolerability of atezolizumab (atezo) plus bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC): Pooled analysis of IMmotion150 and IMmotion151 by Suarez, C., Choueiri, T.K., McDermott, D.F., Escudier, B., Atkins, M.B., Powles, T.B., Rini, B.I., Motzer, R.J., Pal, S.K., Fong, L., De Giorgi, U., Wang, Y., Khaznadar, T., Di Nucci, F., Kaiser, C., Tayama, D., Donskov, F.

Get full text

Monocytes and neutrophils as 'bad guys' for the outcome of interleukin-2 with and without histamine in metastatic renal cell carcinoma - results from a randomised phase II trial by DONSKOV, F, HOKLAND, M, MARCUSSEN, N, TORP MADSEN, H. H, VON DER MAASE, H

“…Histamine (HDC) inhibits formation and release of phagocyte-derived reactive oxygen species, and thereby protects natural killer (NK) and T cells against…”
Get full text

4LBA Cabozantinib versus everolimus in patients with advanced renal cell carcinoma: Results of the randomized phase 3 METEOR trial by Choueiri, T, Escudier, B, Powles, T, Mainwaring, P, Rini, B, Donskov, F, Hammers, H, Hutson, T, Roth, B, Peltola, K, Lee, J.L, Heng, D, Schmidinger, M, Borgman-Hagey, A, Hessel, C, Scheffold, C, Schwab, G, Tannir, N, Motzer, R

Get full text

3LBA CheckMate 025: a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC) by Sharma, P, Escudier, B, McDermott, D.F, George, S, Hammers, H.J, Srinivas, S, Tykodi, S.S, Sosman, J.A, Procopio, G, Plimack, E.R, Castellano, D, Gurney, H, Donskov, F, Bono, P, Wagstaff, J, Gauler, T.C, Ueda, T, Xu, L.A, Waxman, I.M, Motzer, R.J

Get full text